Skip to main content

Table 2 Clinical and laboratory findings during follow up

From: Methotrexate therapy impacts on red cell distribution width and its predictive value for cardiovascular events in patients with rheumatoid arthritis

  CV-Event P
Yes (n = 23) No (n = 362)
DAS 28 at follow up, mean (SD) 3,12 (0,93) 2,82 (1,37) 0,252
MCV at follow up, mean (SD) 86,6 (5,97) 87,2 (5,7) 0,533
RDW at follow up, mean (SD) 15,1 (2,2) 14,3 (1,5) 0,130
DMARDs at follow up, n (%)
 Methotrexate 15 (65,2%) 207 (57,2%) 0,451
 Sulfasalazine 0 9 (2,5%) 0,445
 Hydroxychloroquine 2 (8,7%) 27 (7,5%) 0,868
 Leflunomide 3 (13%) 15 (4,1%) 0,050
 Azathioprine 0 6 (1,7%) 0,533
 Glucocorticoids 8 (34,8%) 133 (37,5%) 0,810
 bDMARD 8 (34,8%) 130 (36%) 0,892
  1. Clinical and laboratory findings during follow up associated with CV event, significance level at p level ≤ 0,05 –see legend to Table 1, DAS 28 disease activity score 28, MCV mean corpuscular volume, (b)DMARD (biological) disease modifying antirheumatic drug